Korean biotech companies said they would gather at Bio Korea 2022, a health and pharmaceutical industry trade fair, to discuss business strategies in the post-Covid-19 era.The Korea Health Industry Development Institute (KHIDI) and North Chungcheong Province jointly organized the annual event, which
Celltrion Healthcare said that it would expand direct sales, previously limited to only some products, to all products in the European market.The company has sold Remsima (ingredient: infliximab), a biosimilar for treating autoimmune diseases, directly in Europe since 2019. Since then, despite inten
Matica Biotechnology, a U.S. affiliate of CHA Biotech, said that the company has dedicated its contract development manufacturing organization (CDMO) facility for cell and gene therapy.Located in College Station, Texas, Matica’s new CDMO manufacturing facility has a 500L bioreactor and meets the FDA
Samsung Biologics said that it achieved the highest quarterly performance ever in the first quarter by posting 511.3 billion won ($401.6 million) in sales in the first quarter of this year, up 96 percent from the same period in 2021.The company also registered 176.4 billion won in operating profit,
Celltrion said that it recently completed a patent agreement with AbbVie, the developer of the blockbuster autoimmune disease treatment Humira (Ingredient: adalimumab), and will start selling its biosimilar version, Yuflyma, in the U.S. from July 2023.Celltrion applied Yuflyma to the U.S. Food and D
Thelma Therapeutics requested the Korea Exchange to evaluate whether the company duly implemented its business improvement plan.Attention is on whether the biopharmaceutical firm, whose stock transaction has been suspended since late March last year, can escape from the risk of being delisted from t
President-elect Yoon Suk-yeol vowed to give full support to the bio-health industry to make it “a second semiconductor,” a major driver of the Korean economy.The new government will establish a Pharmaceutical and Biopharmaceutical Innovation Committee, bring up physician-scientists, operate a regula
“STgen Bio’s entry into the global market and a growth to become a global contract development and manufacturing organization (CMDO) will play a significant role for Dong-A Socio Group to become a global healthcare player by 2025.”STgen Bio CEO Choi Kyung-eun said this and other remarks at a recent
KangStem Biotech said that it has signed a contract development and manufacturing organization (CDMO) contract with YJ Cerapeutics to treat cross-differentiated neural progenitor cells.Under the accord, KangStem will develop and produce YJ Cerapeutics' cross-differentiated neural progenitor cell the
Exostemtech said it applied for a phase 1 trial of EST-P-EXO1, an osteoarthritis treatment candidate, to the Food and Drug Safety Ministry.If the company gets the nod for the study, EST-P-EXO1 will become the first exosome-based treatment that enters a clinical trial in Korea.According to Exostemtec
The lockdown of Shanghai prompted by Covid-19 has entered the third week, and it is likely to disrupt Korean pharmaceutical and biotech firms’ clinical trials there, observers said.According to ClinicalTrials.gov, a U.S. clinical trial registry site, SK Biopharm and HanAll Biopharma were conducting
Celltrion said it has released the phase 3 clinical trial results of CT-P16, a biosimilar for Avastin (ingredient: bevacizumab), at the American Association for Cancer Research 2022 (AACR).AACR is an international cancer association with over 40,000 members from 120 countries. This year, the meeting
3billion, a rare disease genetic test developer, said it would enter the U.S. market in earnest.The Korean company obtained the College of American Pathologists (CAP) certification in November and recently raised 13.1 billion won ($10.5 million) pre-IPO funding to tap the global diagnostic market.Th
With cannabis-based foods and pharmaceutical products getting more popular worldwide, governments and companies are closely monitoring how the cannabis market is moving.An industry report said that the Korean government is also showing signs of easing regulations on medical cannabis.On Monday, the K
NKMax, a biotech firm focusing on natural killer (NK) cell therapies, announced on Monday that an abstract of a phase 1 study in solid cancer (sarcoma) has been accepted for presentation at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in June.NKGen Biotech, a subsi
“I don’t think we can produce influenza vaccine SKYCellflu this year. So we had to choose between a Covid-19 vaccine and a flu vaccine with limited manufacturing lines. So we decided to make a Covid-19 vaccine from the public health aspect because the world population needs it a little more.”Ahn Jae
Korean conglomerates, including retail giant Lotte Group and shipbuilding behemoth Hyundai Heavy Industries, have picked the biotech and healthcare industries as their future growth engines.Industry attention is on how their business expansion with enormous funding power will affect the bio and heal
Celltrion began to work on type-2 diabetes treatment. After securing DPP-4 inhibitor Nesina (alogliptin) through the acquisition of Takeda Pharmaceutical’s Asia Pacific assets, Celltrion is likely to release a combination drug, too, industry officials said.On Tuesday, the Ministry of Food and Drug S
Samsung Biologics said it would purchase a land site to construct its fifth and sixth plants in Songdo, Incheon.In a public filing on Tuesday, the company said it planned to buy “Songdo International City High-tech Industrial Cluster (C)) (430 Songdo-dong, Yeonsu-gu, Incheon)” from the Incheon Free
TiumBio said it would release study results showing that its investigational immunotherapy has superior immune activation than MedPacto’s vactosertib.MedPacto brushed off TiumBio’s announcement, calling it “meaningless,” but the company seemed upset about it at the same time.TiumBio disclosed the ab